Skip to contentA
Aquestive Therapeutics, Inc.
A
AQSTAquestive Therapeutics, Inc. Q3 2023 · 10-Q
Revenue$13.00M$13.00M+13.4% vs Q3 2022 Net Income-$2.04M-$2.04MN/M vs Q3 2022 EPS Diluted-$0.03-$0.03N/M vs Q3 2022 Operating Income-$2,377,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Aquestive Therapeutics, Inc. · CIK 1398733 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$2,498,000N/M Margins · derivedOperating margin-18.3%+58.9 pt vs Q3 2022
Net margin-15.7%+93.7 pt vs Q3 2022
ended Sep 30, 2023 · filed Nov 6, 2023 · 37 d after period end